In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Genzyme gets rights to Osiris's Prochymal and Chondrogen; deal terminated

Executive Summary

In a deal potentially worth $1.38bn in up-fronts and total milestones, Genzyme received exclusive rights to develop and commercialize stem cell company Osiris Therapeutics' Prochymal and Chondrogen adult stem cell products worldwide, with the exception of the US and Canada, where Osiris retains rights; and in Japan, where Prochymal was previously licensed in the graft-versus-host disease (GvHD) indication.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register